Global In-vitro Colorectal Cancer Screening Tests Market by Test Type (Fecal Immunochemical Test (FIT), Stool DNA Test, Guaiac-based Fecal Occult Blood Test (gFOBT)), by Technology (Enzyme Immunoassay (EIA), Polymerase Chain Reaction (PCR)), by End-Use (Hospitals, Diagnostic Laboratories), and by Region; Insights & Forecast (2024 – 2030)

As per Intent Market Research, the In-vitro Colorectal Cancer Screening Tests Market was valued at USD 5.4 Billion in 2024-e and will surpass USD 8.6 Billion by 2030; growing at a CAGR of 8.2% during 2025 - 2030.

The in-vitro colorectal cancer screening tests market is experiencing significant growth due to the increasing demand for early detection of colorectal cancer, a leading cause of cancer-related deaths globally. These screening tests are non-invasive and are primarily used for the detection of potential abnormalities, providing an effective means of identifying individuals at higher risk for colorectal cancer. With advancements in technology, these tests are becoming more accurate, efficient, and accessible, thereby contributing to the overall market expansion. The growing awareness about the importance of early cancer detection, coupled with rising health consciousness, further bolsters the demand for such diagnostic tools.

Fecal Immunochemical Test (FIT) is Fastest Growing Owing to Its Non-Invasive Nature

Among the various test types available for colorectal cancer screening, the fecal immunochemical test (FIT) is witnessing the fastest growth. FIT is a non-invasive test that detects occult blood in stool, which is one of the earliest indicators of colorectal cancer. The test's growing popularity can be attributed to its ease of use, affordability, and high sensitivity for detecting blood in the stool, making it a preferred choice for both patients and healthcare providers. Furthermore, FIT's ability to detect colorectal cancer at an early stage is a key factor driving its adoption in routine screening programs, especially in high-risk populations.

Polymerase Chain Reaction (PCR) Technology is Largest Owing to Its High Sensitivity

The polymerase chain reaction (PCR) technology is the largest segment in the in-vitro colorectal cancer screening tests market, driven by its unparalleled sensitivity and precision in detecting genetic mutations associated with colorectal cancer. PCR allows for the amplification and detection of DNA or RNA from stool samples, providing accurate results even with a small number of cancerous cells present. Its ability to identify gen

etic markers specific to colorectal cancer gives it a significant advantage in early detection, making it a vital tool in personalized medicine and targeted therapies.

Hospitals are Largest End-Use Industry Due to High Volume of Screening

Hospitals are the largest end-use industry for in-vitro colorectal cancer screening tests. This is due to the high volume of patients seeking screening as part of routine check-ups or for early detection of cancer, particularly among those with a family history of colorectal cancer. Hospitals have the necessary infrastructure, skilled professionals, and diagnostic equipment to conduct these tests at scale, making them the primary setting for most colorectal cancer screenings. Additionally, hospitals are increasingly integrating these tests into their cancer prevention programs, further driving the growth of this segment.

North America is the Largest Region Driven by High Awareness and Healthcare Infrastructure

North America is the largest region in the in-vitro colorectal cancer screening tests market, with the United States leading the charge. This is largely due to the high awareness levels regarding colorectal cancer and the availability of advanced healthcare infrastructure that supports the adoption of early detection tests. The region also benefits from robust reimbursement policies and government initiatives that encourage regular screenings, particularly for individuals aged 50 and above. The presence of key market players and ongoing research and development activities further contribute to the region's dominance in this market.

Leading Companies and Competitive Landscape

The in-vitro colorectal cancer screening tests market is highly competitive, with several prominent companies driving innovation and expansion. Key players include Abbott Laboratories, F. Hoffmann-La Roche AG, Exact Sciences Corporation, and Thermo Fisher Scientific, among others. These companies are focusing on enhancing their product offerings through technological advancements such as the development of more accurate PCR-based tests and improved fecal immunochemical test kits. Additionally, partnerships and collaborations with hospitals and diagnostic laboratories are crucial strategies adopted by market players to expand their reach and enhance customer access to screening services. The competitive landscape is marked by a strong emphasis on product innovation, regulatory approvals, and increasing healthcare partnerships to capitalize on the growing demand for early cancer detection.

Recent Developments:

• Exact Sciences launched an updated version of its Cologuard stool DNA test, improving its accuracy in detecting colorectal cancer in early stages.
• Abbott Laboratories received FDA approval for its new stool-based colorectal cancer test, offering a more affordable option for early detection.
• Roche Diagnostics acquired a leading molecular diagnostics company to strengthen its colorectal cancer screening portfolio with innovative PCR-based tests.
• Quest Diagnostics expanded its colorectal cancer screening services by integrating at-home testing kits with its laboratory services.
• Hologic Inc. launched a new multi-target stool DNA test aimed at improving the detection rate of colorectal cancer through its advanced molecular platform.

List of Leading Companies:

• Abbott Laboratories
• Exact Sciences Corporation
• Roche Diagnostics
• Quest Diagnostics
• Hologic Inc.
• F. Hoffmann-La Roche Ltd.
• CardioDx, Inc.
• Sierra Diagnostics
• Cigna Corporation
• LabCorp
• Cologuard (Exact Sciences)
• Eiken Chemical Co. Ltd.
• Epigenomics AG
• MDXHealth
• Biocartis

Report Scope: